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Abstract
Background: 3’,4’-Dihydroxyflavonol (DiOHF) is an effective antioxidant that acutely preserves nitric oxide (NO) activity in
the presence of elevated reactive oxygen species (ROS). We hypothesized that DiOHF treatment (7 days, 1 mg/kg per day
s.c.) would improve relaxation in mesenteric arteries from diabetic rats where endothelial dysfunction is associated with
elevated oxidant stress.
Methodology/Principal Findings: In mesenteric arteries from diabetic rats there was an increase in ROS, measured by L-012
and 2’,7’-dichlorodihydrofluorescein diacetate fluorescence. NADPH oxidase-derived superoxide levels, assayed by lucigenin
chemiluminescence, were also significantly increased in diabetic mesenteric arteries (diabetes, 48926946 counts/mg versus
normal 24866344 counts/mg, n = 7–10, p,0.01) associated with an increase in Nox2 expression but DiOHF (20946300
counts/mg, n = 10, p,0.001) reversed that effect. Acetylcholine (ACh)-induced relaxation of mesenteric arteries was
assessed using wire myography (pEC50 = 7.9460.13 n = 12). Diabetes significantly reduced the sensitivity to ACh and
treatment with DiOHF prevented endothelial dysfunction (pEC50, diabetic 6.8660.12 versus diabetic+DiOHF, 7.4960.13,
n = 11, p,0.01). The contribution of NO versus endothelium-derived hyperpolarizing factor (EDHF) to ACh-induced
relaxation was assessed by evaluating responses in the presence of TRAM-34+apamin+iberiotoxin or N-nitro-L-
arginine+ODQ respectively. Diabetes impaired the contribution of both NO (maximum relaxation, Rmax diabetic 2467
versus normal, 68610, n = 9–10, p,0.01) and EDHF (pEC50, diabetic 6.6360.15 versus normal, 7.1460.12, n = 10–11, p,0.01)
to endothelium-dependent relaxation. DiOHF treatment did not significantly affect the EDHF contribution but enhanced
NO-mediated relaxation (Rmax 6966, n = 11, p,0.01). Western blotting demonstrated that diabetes also decreased
expression and increased uncoupling of endothelial NO synthase (eNOS). Treatment of the diabetic rats with DiOHF
significantly reduced vascular ROS and restored NO-mediated endothelium-dependent relaxation. Treatment of the diabetic
rats with DiOHF also increased eNOS expression, both in total and as a dimer.
Conclusions/Significance: DiOHF improves NO activity in diabetes by reducing Nox2-dependent superoxide production
and preventing eNOS uncoupling to improve endothelial function.
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Introduction
Endothelial dysfunction, characterized by the impairment of
endothelium-dependent relaxation, is recognised as a critical and
initiating factor in the development of diabetes-induced vascular
complications [1,2]. Oral hypoglycaemic agents and insulin have
been used to treat diabetes but they do not prevent the
development of diabetic vascular complications [3,4,5]. In
diabetes, hyperglycaemia-induced oxygen radical generation,
mainly superoxide anion radicals, play a key role in the
pathogenesis of vascular complications [6,7,8]. Despite this,
clinical trials with antioxidants have failed to clearly demonstrate
any beneficial effect on vascular function [9,10]. More effective
antioxidants, acting perhaps by targeting the specific sources of
reactive oxygen species (ROS) might prove more beneficial than
direct scavenging strategies [8,11,12]. Potential targets for
pharmacological therapies include NADPH oxidase, endothelial
nitric oxide synthase (eNOS) and mitochondria all of which have
been reported to be sources of increased ROS in diabetes [2,13].
Flavonols are one class of a large family of plant-derived
polyphenolic compounds known as flavonoids. They exhibit a
variety of biological actions such as antithrombotic, anti-
inflammatory, antioxidant and vasorelaxant effects [14,15]. There
is growing evidence that consumption of a flavonoid-rich diet
reduces the risk of cardiovascular disease states associated with
overproduction of ROS [16,17]. In addition, a number of studies
have shown that, in animal models of diabetes, chronic treatment
with the flavonol quercetin preserves endothelial function [18],
reduces pancreatic beta-cell death [19] and protects against
diabetic nephropathy [20].
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Structure-activity relationship studies have demonstrated that a
synthetic flavonol, 3’,4’-dihydroxyflavonol (DiOHF) is significantly
more potent than a number of natural flavones and flavonols in its
antioxidant ability [21,22]. In addition, the antioxidant ability of
DiOHF has been shown to preserve endothelial function in the
aorta in the presence of oxidative stress [23,24]. Furthermore,
DiOHF effectively reduces oxidative stress related impairment of
cardiovascular function after ischaemia/reperfusion in rats [23]
and sheep [25,26] and in diabetic aorta [27]. Recently, we have
shown the acute antioxidant activity of DiOHF is able to restore
endothelial function in the diabetic microvasculature [28] but it is
not known whether treatment with DiOHF is able to inhibit the
sources of ROS production[29] in the diabetic microvasculature to
improve endothelial function.
Diabetes-induced endothelial dysfunction is due to the impair-
ment of both NO-mediated and endothelium-dependent hyper-
polarizing factor (EDHF)-type relaxation, which is accompanied
by an increase in Nox2-derived superoxide production and eNOS
uncoupling in the mesenteric artery [30]. Therefore, the aim of the
present study was to investigate whether short term in vivo
treatment with DiOHF preserves microvascular endothelial
function in mesenteric artery from type 1 diabetic rats and, if so,
whether it acts via direct scavenging of ROS and/or by inhibiting
the sources of ROS production in the diabetic microvasculature.
In addition, we also sought to verify whether the antioxidant
activity of DiOHF treatment would have any effect on NO-
mediated relaxation and/or EDHF-type relaxation in the diabetic
arteries.
Results
Body weights and blood glucose
The body weight gained, blood glucose and HbA1c levels of the
rats are shown in Table 1. 8 weeks after treatment with
streptozotocin or vehicle, the body weight gained in normal rats
was significantly greater than in diabetic rats (Table 1). The blood
glucose and HbA1c level of diabetic rats were significantly greater
than normal rats. Treatment with DiOHF had no significant effect
on body weight gain, blood glucose or HbA1c levels in normal rats,
but significantly increased the body weight gain in diabetic rats. In
comparison to DiOHF-treated normal rats, the diabetic rats that
were treated with DiOHF had significantly lower body weight gain
and significantly greater blood glucose and HbA1c level (Table 1).
Effect of DiOHF on ROS production
The ROS level in mesenteric arteries was measured by L-012
chemiluminescence and 2’,7’-dichlorodihydrofluorescein diacetate
(DCFDA) fluorescence. The superoxide and DCFDA-induced
fluorescence levels from diabetic rats were significantly higher than
in normal rats (Figure 1). 7 days treatment with DiOHF
attenuated the generation of superoxide (Figure 1A) and
DCFDA-induced fluorescence levels (Figure 1B) in diabetic rats,
but had no effect in normal arteries. The presence of L-NNA
attenuated the generation of superoxide in diabetic arteries, but
had no effect in either normal or DiOHF-treated arteries.
Apocynin, a ROS scavenger, attenuated the production of
superoxide in arteries from all groups (Figure 1A).
The level of NADPH oxidase-driven superoxide production
detected by L-012-enhanced chemiluminescence in mesenteric
arteries from diabetic rats was significantly increased in compar-
ison to normal rats (Figure 1C). DiOHF treatment of the rats did
not affect superoxide production by mesenteric arteries from
normal rats but significantly reduced levels generated by diabetic
mesenteric arteries to levels observed from normal rats. In all
groups, NADPH oxidase-driven superoxide production from
mesenteric arteries could be inhibited by diphenyl iodonium, a
flavoprotein inhibitor that inhibits NADPH oxidase (Figure 1C).
Effect of DiOHF on vascular function
The level of the reference contraction, high K+ physiological
saline solution (KPSS, 123 mmol/l), was not affected by diabetes
or DiOHF treatment (Figure S1). Diabetes significantly reduced
the sensitivity, but not the maximum relaxation, to ACh in
mesenteric arteries (Figure 2A, Table 2), whereas the sensitivity
(diabetic, 7.9660.20 vs. normal, 7.8960.16, n = 5–6, p.0.05) and
maximum relaxation (diabetic, 10060% vs. normal, 9961%,
n=5–6, p.0.05) to sodium nitroprusside (SNP) were not affected
(Figure 2B). Treatment of normal rats with DiOHF (1 mg/kg s.c.)
for 7 days did not affect responses to ACh, however in mesenteric
arteries from diabetic rats treated with DiOHF, the sensitivity to
ACh was significantly increased in comparison to the response in
mesenteric arteries from untreated diabetic rats (Figure 2, Table 2).
DiOHF treatment did not affect responses to SNP in normal rats
(pEC50 8.1860.18, Rmax 10060%, n=9) or diabetic rats (pEC50
7.8460.18, Rmax 9961%, n=6).
The diabetic arteries also showed a significant increase in
sensitivity to endothelin-1 (ET-1, diabetic, 8.4660.07 vs. normal,
8.1960.06, n = 7–8, p,0.05), without affecting the maximum
contraction. Treatment with DiOHF had no effect in normal
arteries (normal+DiOHF, 8.1660.03, n= 7), but significantly
reduced the sensitivity to ET-1 in diabetic arteries in com-
parison to untreated diabetic arteries (diabetic, 8.4660.07 vs.
diabetic+DiOHF, 8.2060.07, n= 7–8, p,0.05), (Figure 2C).
Relative contribution of NO and EDHF to endothelium-
dependent relaxation
In normal mesenteric arteries, ACh-induced relaxation could be
partly inhibited by either the combination of a NO synthase
Table 1. Mean body weight gained, blood glucose and glycated haemoglobin levels at the end of the experiment of normal and
diabetic rats with or without 39, 49-dihydroxyflavonol (DiOHF, 1 mg/kg s.c. daily for 7 days) treatment.
8 weeks after vehicle or STZ treatment
n Normal n Normal+DiOHF n Diabetic n Diabetic+DiOHF
Body weight gained (g) 22 307612 19 28665 19 126610* 20 177610{{
Blood glucose (mM) 22 8.360.6 19 7.360.6 19 32.460.3* 20 30.260.9{
HbA1c (%) 8 6.160.2 7 5.860.2 10 13.560.5
* 10 12.660.6{
n= the number of rats. * Significantly different from normal group (Bonferroni’s test, p,0.05), { Significantly different to diabetic group, p,0.05, Bonferroni’s test.
{ Significantly different to Normal+DiOHF group, p,0.05, Bonferroni’s test. Results are shown as mean6SEM.
doi:10.1371/journal.pone.0020813.t001
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inhibitor, N-nitro-L-arginine (L-NNA) and a soluble guanylate
cyclase inhibitor, 1H-(1,2,4)-oxadiazolo(4,2-a)quinoxalin-1-one
(ODQ), or KCa channels inhibitors, 1-[(2-chlorophenyl)(diphenyl)-
methyl]-1H-pyrazole (TRAM-34), apamin and iberiotoxin (Ibtx),
to block the intermediate-conductance calcium-activated K+
channel (IKCa),small-conductance calcium-activated K
+ channel
(SKCa) and large-conductance calcium-activated K
+ channel (maxi
KCa) respectively, indicating that both NO and EDHF contributed
to endothelium-dependent relaxation. However, in diabetic
arteries, ACh-induced relaxation could only be inhibited by the
KCa channels inhibitors, suggesting that EDHF was the predom-
inant contributor to endothelium-dependent relaxation in diabe-
tes. In the presence of both NO and EDHF inhibitors,
endothelium-dependent relaxation were abolished in all groups
of rats (Table 2).
Effect of DiOHF on NO-mediated relaxation
To determine the NO-mediated component of the relaxation,
responses to ACh were evaluated in the presence of TRAM-
34+apamin or TRAM-34+apamin+Ibtx. When these responses
were compared between arteries from normal (Figure 3A, Table 2)
and diabetic (Figure 3B, Table 2) rats, it is apparent that diabetes
decreased the maximum relaxation to ACh in the presence of
TRAM-34+apamin (diabetic 6668% vs. normal, 9163%, n= 11–
12, p,0.05). A similar difference was also apparent in the presence
of TRAM-34+apamin+Ibtx (diabetic 3169% vs. normal,
68610%, n= 10, p,0.05), indicating that diabetes impaired the
contribution of NO to endothelium-dependent relaxation. Treat-
ment with DiOHF (1 mg/kg s.c.) for 7 days had no effect in
normal rats but significantly increased the maximum relaxation to
ACh (diabetic 6668% vs. diabetic+DiOHF, 8663%, n= 11,
p,0.05) in the presence of TRAM-34+apamin (Figure 3B, D,
Table 2). A similar finding was observed in DiOHF-treated
diabetic arteries (Figure 3B, D, Table 2) in the presence of TRAM-
34+apamin+Ibtx (diabetic 3169% vs. diabetic+DiOHF, 6966%,
n=11, p,0.05), indicating that DiOHF treatment improved the
contribution of NO to endothelium-dependent relaxation in
diabetic arteries. In addition, in arteries pre-contracted with a
depolarizing solution of 30 mM K+, to eliminate any contribution
of the opening of potassium channels, ACh-induced relaxation was
significantly attenuated in diabetic arteries in comparison to
normal arteries, but this response was significantly improved by 7
days treatment with DiOHF in diabetic rats (Figure 3, Table 2).
The basal level of NO release was assessed by measuring the
contraction induced by L-NNA in arteries with PE-induced tone
(i.e. 20% KPSS) (Figure 2D). The L-NNA-induced contraction
was significantly greater in arteries from normal rats compared
with diabetic rats (normal, 6662% vs. diabetic, 4462%, n= 6–7,
p,0.05), indicating that diabetes impaired the basal release of
NO. Treatment with DiOHF had no effect on L-NNA-induced
contraction in normal arteries (normal+DiOHF, 5767%), but
significantly increased the L-NNA-induced contraction in dia-
betic arteries in comparison to untreated diabetic arteries
(diabetic+DiOHF, 6162% vs. diabetic, 4462%, n= 5–6,
p,0.05).
Effect of DiOHF on EDHF-type relaxation
To characterise EDHF-type relaxation, the contribution of NO
was eliminated by the combination of L-NNA and ODQ. In the
presence of L-NNA+ODQ, the sensitivity to ACh was significantly
lower in the diabetic compared to the normal arteries (diabetic,
6.6360.15 vs. normal, 7.1460.12, n = 10–12, p,0.05), indicating
that diabetes impairs the contribution of EDHF to endothelium-
dependent relaxation. Treatment of normal and diabetic rats with
DiOHF (1 mg/kg s.c.) for 7 days had no significant effect on ACh-
mediated EDHF-type relaxation (Table 2).
The addition of TRAM-34 and apamin to the presence of L-
NNA+ODQ, abolished ACh-induced relaxation in either untreated
diabetic or DiOHF-treated diabetic arteries. In normal or DiOHF-
treated normal arteries, however, ACh continued to cause a
maximum relaxation of almost 60% (Figure 4, Table 2). The
residual relaxation observed in normal and DiOHF-treated normal
arteries could be abolished by the additional presence of Ibtx
Figure 1. ROS measurement in intact mesenteric arteries. A,
Superoxide, B, DCFDA-induced flurorescence levels and C, NADPH-
oxidase activity was increased in diabetic arteries which was reduced
with DiOHF treatment. A, Superoxide levels in diabetic arteries were
attenuated by the presence of L-NNA (100 mM), indicating eNOS
uncoupling. n = 9–10 experiments. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0020813.g001
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(Figure 4A, C, Table 2), suggesting an additional role of other
endothelium-derived factors to cause relaxation in normal arteries,
but not in diabetes.
Effect of DiOHF on Nox2 and NOS expression, and eNOS
uncoupling
Diabetes significantly decreased the expression of total eNOS in
the mesenteric arteries but this was reversed by treatment with
DiOHF (Figure 5A). In addition, diabetes significantly decreased
the proportion of eNOS expressed as a dimer. Treatment of
diabetic rats with DiOHF significantly increased the proportion of
eNOS expressed as a dimer (Figure 5B). The expression of Nox2
was also significantly increased in diabetic arteries compared to
normal arteries. In DiOHF-treated diabetic arteries, Nox2
expression was significantly reduced, but it remained significantly
higher in comparison to DiOHF-normal arteries (Figure 5C).
Treatment with DiOHF in normal rats had no effect on eNOS
and Nox2 expression and inducible-NOS expression was not
detected in any group (data not shown).
Discussion
This study demonstrates that treatment of type 1 diabetic rats
with the synthetic flavonol DiOHF (1mg/kg, per day) for 7 days
reduces the levels of vascular oxidative stress and improves
endothelium-dependent relaxation in mesenteric arteries. Endo-
thelial dysfunction in the diabetic rats is associated with a
decreased contribution of both NO-mediated and EDHF-type
relaxation to endothelium-dependent relaxation. Treatment with
DiOHF improves NO-mediated relaxation in diabetic rats
accompanied by an increased expression of eNOS, reduced
eNOS uncoupling and downregulation of Nox2 expression.
Effect of DiOHF on endothelial function
In the present study, diabetes increases the level of vascular
ROS production, associated with an increase in Nox2 expression
and a selective impairment of endothelium-dependent relaxation,
as we and others have previously described [1,30,31,32].
Treatment with the synthetic flavonol DiOHF (1mg/kg, per day)
for 7 days in vivo reduces the levels of oxidative stress, at least in
part by inhibiting superoxide production by Nox2 and uncoupled
eNOS in the diabetic mesenteric arteries, and improves endothe-
lium-dependent relaxation in mesenteric arteries from diabetic
rats. These observations are consistent with other studies that have
demonstrated that treatment with flavonols in diabetic rats reduces
vascular oxidant stress and preserves endothelial function in
conduit arteries such as the aorta [18,27] or renal vasculature [20].
Whilst there are several reports that flavonols attenuate diabetes-
Figure 2. Vascular function in mesenteric arteries. Cumulative concentration-response curves to A, ACh, B, SNP, C, ET1 and D, basal NO release
in endothelium-intact mesenteric arteries. In each group of experiments (A, B), mesenteric arteries were precontracted with phenylephrine to similar
level: (A) normal 5963, normal+DiOHF 5963, diabetic 6262, diabeticDiOHF 6063, (B) normal 5862, normal+DiOHF 5763, diabetic 6163,
diabeticDiOHF 5964%KPSS, n = 5–12 experiments. Results are shown as mean6SEM. * p,0.05, ** p,0.01. See Table 2 or results section for pEC50
and Rmax values.
doi:10.1371/journal.pone.0020813.g002
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induced endothelial dysfunction, the mechanism of the vasopro-
tective effect of flavonols remain poorly understood, in particular
the effect of flavonols on the relative contribution of NO and
EDHF to endothelium-dependent relaxation.
Effects of DiOHF on NO-mediated relaxation
In order to evaluate NO-mediated relaxation, the EDHF-type
relaxation was inhibited either by endothelial KCa channel
blockers or by the presence of a depolarizing K+ solution. This
confirmed an impaired release of NO, as under those conditions
the maximum relaxation to ACh was decreased in the diabetic
mesenteric arteries in comparison to normal arteries. Treatment
with DiOHF in vivo for 7 days significantly increased the maximum
relaxation to ACh in diabetic arteries in comparison to untreated
diabetic rats. In addition to stimulated NO release, basal release of
NO was also decreased in diabetic mesenteric arteries as
demonstrated by impaired contraction in response to NOS
inhibition, and this was also reversed in DiOHF treated diabetic
arteries. Hence, treatment with DiOHF preserves NO-mediated
relaxation in diabetic small mesenteric arteries.
Consistent with impairment of NO-mediated relaxation, we
found that the expression of total eNOS was decreased and
uncoupling of eNOS was indicated by the decreased proportion of
eNOS expressed as a dimer in the diabetic mesenteric vasculature.
This suggests that in the diabetic rats, in addition to producing
NO, eNOS is producing superoxide, further demonstrated by a
reduction of superoxide levels in the diabetic mesenteric arteries in
the presence of NOS inhibition [13,33]. However, in DiOHF-
treated diabetic rats, the expression of eNOS was increased to
levels that were comparable to normal rats. In addition, treatment
with DiOHF promoted the re-coupling of eNOS, which was
shown by the increased proportion of eNOS expressed as a dimer
compared to untreated diabetic rats and the lack of inhibitory
effect of L-NNA on superoxide production in DiOHF-treated
arteries.
A further contributing factor to the restoration of NO activity by
DiOHF treatment could be the reduction of vascular superoxide
production in diabetic mesenteric arteries, which could then
increase the bioavailability of NO by preventing the degradation
of NO by superoxide to form peroxynitrite. The reduction of
vascular ROS activity in the DiOHF-treated diabetic vasculature
could be either due to the rapid free radical scavenging effect of
DiOHF to preserve NO bioavailability [23] or by decreasing the
expression and/or activity of the enzymatic sources of superoxide
production in the vasculature such as the catalytic subunit of
NADPH oxidases, Nox2 and its regulatory subunits [34]. Taken
together, DiOHF treatment protects the beneficial activity of NO
by increasing eNOS expression, preventing eNOS uncoupling and
decreasing Nox2-dependent superoxide production in the diabetic
mesenteric arteries.
Effect of DiOHF on EDHF-type relaxation
In the rat mesenteric artery, endothelium-dependent relaxation
is mediated by NO, the classical EDHF pathway and there is also
a role for the non-classical EDHF pathway [35]. To investigate the
role of EDHF, we assessed endothelium-dependent relaxation in
the presence of L-NNA and ODQ to inhibit NO synthesis and
sGC activity respectively. The guanylate cyclase inhibitor was used
in addition to the NOS inhibitor to ensure the inhibition of the
actions of NO derived from non-NOS sources such as nitro-
sothiols, which we have previously reported to act as a NO source
in diabetes [33]. In the presence of L-NNA+ODQ, the sensitivity
to ACh was decreased in diabetic arteries when compared to
normal arteries, indicating that diabetes impaired of the
contribution of EDHF-type relaxation, which is consistent with
several other studies [36,37,38]. Treatment with DiOHF caused a
modest improvement in EDHF-type relaxation in diabetic
mesenteric arteries, but the change was not statistically significant.
It should be noted however that whereas ACh-induced relaxation
in the presence of L-NNA+ODQ was impaired in diabetes
compared to normal arteries, under the same conditions there was
no significant difference in the responses to ACh in arteries from
normal and diabetic treated with DiOHF. Thus, the evidence is
Table 2. Effect of L-NNA, ODQ and potassium channel blockers on ACh-induced relaxation of mesenteric arteries from normal and
diabetic rats with or without 39, 49-dihydroxyflavonol (DiOHF, 1 mg/kg s.c. daily for 7 days) treatment in the presence of
indomethacin.
Normal Normal + DiOHF Diabetic Diabetic + DiOHF
n pEC50 Rmax (%) n pEC50 Rmax (%) n pEC50 Rmax (%) n pEC50 Rmax (%)
Control 12 7.9460.13 10060 10 7.7860.16 10060 11 6.8660.12{ 9763 11 7.4960.131 10060
TRAM-34 + apamin 12 7.2660.19* 9163 9 6.9360.22* 9262 11 6.8660.16 6668*{ 11 7.0460.11* 8663*1
TRAM-34 + apamin+Ibtx 10 6.8360.15* 68610* 9 6.8460.19* 71611* 10 ND 3169*{ 11 6.9860.12* 6966*1
30 mM K+ 8 6.9160.10* 7864* 9 7.2860.11*{ 7364* 8 6.3560.07*{ 5265*{ 7 6.8160.13*{1 7062*1
L-NNA + ODQ 12 7.1460.12* 10060 10 7.0760.15* 9861 10 6.6360.15{ 9761 11 6.8560.12* 9961
L-NNA + ODQ +
TRAM-34 + apamin
10 5.4860.23* 59610* 10 6.1060.30* 7069* 6 ND 161*{ 7 ND 262*{
L-NNA + ODQ +
TRAM-34 + apamin+Ibtx
7 ND 363* 5 ND 262*
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the absence (control), or in the presence of TRAM-34 (1 mM)+apamin (1 mM), TRAM-34
(1 mM)+apamin (1 mM) +Ibtx (100 nM), 30 mM K+, L-NNA (100 mM)+ODQ (10 mM), L-NNA (100 mM)+ODQ (10 mM)+TRAM-34 (1 mM)+apamin (1 mM) or L-NNA
(100 mM)+ODQ (1 mM)+TRAM-34 (1 mM)+apamin (1 mM)+Ibtx (100 nM) in endothelium intact mesenteric arteries. All experiments were conducted in the presence of
indomethacin (10 mM). n = the number of experiments.
*Significantly different to control within each group, p,0.05, Dunnet’s test,
{Significantly different to normal within inhibitor group, p,0.05, Bonferroni’s test.
{Significantly different to normal+DiOHF within inhibitor group, p,0.05, Bonferroni’s test.
1Significantly different to diabetic within inhibitor group, p,0.05, Bonferroni’s test. Results are shown as mean6SEM, ND= Not determined.
doi:10.1371/journal.pone.0020813.t002
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equivocal as to whether DiOHF improves EDHF-type relaxation
in the diabetic mesenteric arteries.
The cause of the impairment of EDHF-type relaxation in
diabetes remains controversial [30,37,39,40,41,42] but is partly
attributed to an overproduction of ROS. Indeed, Ma et al., (2008)
demonstrated that superoxide anions generated by auto-oxidation
of pyrogallol could impair EDHF responses in rat mesenteric
arteries, an effect which could be reversed by the acute presence of
the flavones, apigenin and/or luteolin, in the tissue bath [43]. In
the present study, it is important to note that the final
administration of the DiOHF was more than 24 hours before
the conduct of all experiments. Although there appears to be no
information available regarding the pharmacokinetics of flavonols
in rats, in humans it is reported that quercetin reaches peak plasma
concentrations within 2–5 hours after oral ingestion and is
predominantly excreted in the urine within 5–12 hours [44,45].
Given the structural similarities between quercetin and DiOHF, it
is unlikely that there will be any acute effect of DiOHF during
experimentation. Therefore, the in vivo effect of DiOHF on EDHF-
type relaxation remains to be elucidated.
Conclusion
We have demonstrated that the synthetic flavonol DiOHF
increases NO activity to improve endothelial function in diabetic
microvasculature. It was less certain as to whether DiOHF
treatment had a beneficial effect on the EDHF-type component of
endothelium-dependent relaxation. The protective actions of
DiOHF occur through at least two mechanisms. The flavonol is
able to rapidly scavenge ROS and/or inhibit the enzymatic source
for superoxide production to reduce inactivation of NO. In
addition, treatment with DiOHF in vivo for 7 days prevents eNOS
uncoupling and thus helps to maintain endothelium-dependent
relaxation. The beneficial effect of DiOHF to protect NO activity
found in this study indicates that it has potential as a therapeutic
agent for use in the prevention of the microvascular complications
of diabetes.
Methods
Ethics statement: All procedures were approved by the Animal
Experimentation Ethics Committee of RMIT University (approval
number 0822) and conformed to the National Health and Medical
Research Council of Australia code of practice for the care and use
of animals for scientific purposes.
Induction of diabetes
Male 6–8 week old Wistar rats weighing approximately 200 g
(Animal Resource Centre, Perth, WA, Australia) were randomly
Figure 3. Contribution of NO to endothelium-dependent relaxation in mesenteric arteries. NO-mediated relaxation in mesenteric arteries
isolated from A, normal, B, diabetic, C, normal+DiOHF, D, diabetic+DiOHF rats. In each group of experiments, arteries were precontracted to similar
level: A, 5763, B, 5862, C, 6164, D, 5962%KPSS, n = 9–15 experiments. Results are shown as mean6SEM. See Table 2 for values.
doi:10.1371/journal.pone.0020813.g003
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divided into two groups: normal and diabetic. Type 1 diabetes
was induced by a single injection of streptozotocin (STZ, 50 mg/
kg) into the tail vein after the rats were fasted overnight. The
control groups received an equivalent volume of the vehicle
(0.1 mol/l citrate buffer, pH 4.5) alone. Once the rats were
rendered diabetic (blood glucose .25 mmol/l) the following
week after STZ injection, all diabetic rats were maintained on a
low insulin dose (4–5 IU, s.c., 3 injections per week, Protaphane,
Novo Nordisk, NSW, Australia) to promote weight gain and
reduce mortality [46]. At the end of the experimental period,
blood samples were obtained from the left ventricle and the
glucose concentration and glycated haemogloblin (HbA1c) were
measured using a one touch glucometer (Roche, Sydney, NSW,
Australia) and Micromat HbA1c analyser (Biorad, Sydney, NSW,
Australia) respectively.
DiOHF treatment
After seven weeks of STZ-induced diabetes, the 2 groups of rats
were further divided into 2 groups (Normal, Normal+DiOHF,
Diabetic, Diabetic+DiOHF) receiving either vehicle (10%
DMSO+90% peanut oil) or (DiOHF, 1mg/kg s.c. per day) for a
period of 7 days. The last dose of DiOHF was administered at least
24 hours prior to the start of experimentation.
Isolation of mesenteric arteries
Eight weeks after STZ treatment, the rats were killed with
pentobarbitone sodium (325 mg/kg, i.p, Virbac, Australia). The
mesenteric arcade was isolated and immediately placed in ice cold
Krebs bicarbonate solution (118 mmol/l NaCl, 4.7 mmol/l KCl,
1.18 mmol/l MgSO4, 1.2 mmol/l KH2PO4, 25 mmol/l NaHCO3,
11.1 mmol/l D-glucose, and 1.6 mmol/l CaCl2) containing
indomethacin (10 mmol/l), a non-selective cyclo-oxygenase (COX)
inhibitor, to inhibit the synthesis of prostanoids. Our preliminary
data suggested that there is no significant contribution of
prostanoids to endothelium-dependent in mesenteric arteries from
all groups of rats (data not shown). Small mesenteric arteries (third-
order branch of the superior mesenteric artery, internal diameter
,300 mm) were isolated, cleared of fat and connective tissue, cut
into 2 mm long rings and mounted on a Mulvany-Halpern
myograph (model 610M, Danish Myo Technology, Aarhus,
Denmark). After the arteries were mounted, the vessels were
allowed to stabilize at zero tension for 15 min before normalisation.
The passive tension-internal circumference was determined by
stretching to achieve an internal circumference equivalent to 90% of
that of the blood vessel under a transmural pressure of 100 mmHg
[47,48]. All experiments were performed at 37uC and the baths
were bubbled with carbogen (95% O2 and 5% CO2).
Figure 4. Contribution of EDHF to endothelium-dependent relaxation in mesenteric arteries. EDHF-type relaxation in mesenteric arteries
isolated from A, normal, B, diabetic, C, normal+DiOHF, D, diabetic+DiOHF rats. In each group of experiments, arteries were precontracted with
phenylephrine to similar level: A, 6263, B, 6364, C, 6364, D, 6162%KPSS, n = 5–12 experiments. Results are shown as mean6SEM. See Table 2 for
values.
doi:10.1371/journal.pone.0020813.g004
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Assessment of vascular reactivity
Thirty minutes after normalization, vessels were maximally
contracted with KPSS (123 mmol/l). After several washouts using
normal Krebs solution, basal tension was regained. To assess the
integrity of the endothelium, mesenteric arteries were precon-
tracted to ,50–60% of the KPSS response with phenylephrine
(0.1–3 mmol/l) and a high concentration of acetylcholine (ACh,
10 mmol/l) was used to relax the artery rings. ACh-induced
relaxation was greater than 80% of the precontracted tone in all
cases, indicating that the endothelium was functionally intact.
After further washouts, arteries were again precontracted to a
similar level using phenylephrine (0.1–3 mmol/l) or in some cases
30 mmol/l K+, and cumulative concentration-response curves to
ACh (0.1 nmol/l–10 mmol/l) and SNP (0.01 nmol/l–10 mmol/l)
were determined. In addition, responses to ACh and SNP were
examined after 20 minutes incubation with different combinations
of L-NNA (100 mmol/l), a non-selective nitric oxide synthase
(NOS) inhibitor, ODQ (10 mmol/l), a soluble guanylate cyclase
(sGC) inhibitor, TRAM-34 (1 mmol/l), a selective blocker of the
intermediate-conductance calcium-activated K+ channel (IKCa or
KCa3.1), ibtx (100 nmol/l), a selective blocker of maxi KCa and
apamin (1 mmol/l), a SKCa inhibitor.
To evaluate the constrictor reactivity, cumulative concentra-
tion-response curves to ET-1 (0.1 nmol/l–0.1 mmol/l) were
constructed in the absence of indomethacin.
Assessment of basal release of NO in mesenteric arteries
In another separate set of experiments, the effect of diabetes on
basal levels of NO release was also examined in the absence of
indomethacin through the addition of L-NNA (100 mmol/l) in
endothelium-intact rings precontracted with phenylephrine (10–
100 nmol/l) to approximately ,20% KPSS. Under those
conditions a contractile response to L-NNA was considered to
reflect the level of the basal release of NO [30].
Western Blot
Western blots were performed as described previously [30] with
the following modifications. Endothelium-intact mesenteric arter-
ies from 2 animals from the same treatment group were pooled
and considered as n= 1. Equal amounts of protein homogenate
were subjected to SDS-PAGE and western blot analysis with
mouse/rabbit primary antibodies (all 1:1000, overnight, 4uC)
against endothelial NO synthase (eNOS), inducible-NOS, Nox2
(all BD Transduction Laboratories, Lexington, KY, USA). To
normalize for the amount of protein, membranes were reprobed
with a loading control antibody (actin). All proteins were detected
by enhanced chemiluminescence (Amersham, GE Healthcare,
Sydney, NSW, Australia) after incubation with anti-mouse/rabbit
secondary antibody (Millipore, Billerica, MA, USA) for 1 hour at
room temperature (1:2000). All protein bands were quantified by
densitometry (Biorad Chemidoc, Sydney, NSW, Australia) and
expressed as a ratio of the loading control. To investigate eNOS
homodimer formation in the tissue, a non-boiled sample was
resolved by 6% SDS-PAGE at 4uC [49], and the membranes were
probed and visualized as described above.
Measurement of ROS in mesenteric artery
Two different methods of ROS measurement were employed.
Superoxide production in the mesenteric artery was measured
using L-012 as previously described [30]. Mesenteric arteries were
incubated at 37uC for 30 minutes in Krebs-HEPES buffer either
alone, in the presence of apocynin, a ROS scavenger [50]
(300 mmol/l) or L-NNA (100 mmol/l), which determines NOS-
derived superoxide production. 300 mL of Krebs-HEPES buffer,
containing L-012 (100 mmol/l, Wako Pure Chemicals, Osaka,
Japan) and the appropriate treatments were placed into a 96-well
Optiplate, which was loaded into a Polarstar Optima photon
counter (BMG Labtech, Melbourne, VIC, Australia) to measure
background photon emission at 37uC. After background counting
was completed, a single ring segment of mesenteric artery was
added to each well and photon emission was re-counted. Reactive
oxygen species (H2O2) were measured with DCFDA [51] with the
following modification. Rings of mesenteric artery were loaded
with DCFDA solution (10 mmol/l) for 60 min, followed by 3
washes in Krebs-HEPES buffer. Background fluorescence was
measured after excitation at 485 nm and emission at 520 nm.
After being rinsed three times with Krebs buffer to remove excess
probe, a single segment of the mesenteric artery was added to each
well, and fluorescence intensity was recounted. The luminescence
and fluorescence counts were normalized with dry tissue weight.
NADPH oxidase activity
NADPH oxidase-driven superoxide production in the mesenteric
artery was measured using lucigenin-enhanced chemiluminescence.
Mesenteric arteries were preincubated for 45 min at 37uC in Krebs–
HEPES buffer containing diethylthiocarbamic acid (1 mmol/l), to
inactivate superoxide dismutase, and NADPH (100 mmol/l) as a
substrate for NADPH oxidase, and either alone or in the presence of
diphenylene iodonium (5 mmol/l), as a flavoprotein inhibitor that
inhibits NADPHoxidase. 300 mL of Krebs-HEPES buffer containing
lucigenin (5 mmol/l) and the appropriate treatments were placed into
a 96-well Optiplate, and superoxide production was measured and
quantified as previously described [27].
Reagents
All drugs were purchased from Sigma-Aldrich (St Louis, MO,
USA), except for acetylcholine perchlorate (BDH Chemicals, Poole,
Dorset, UK), DiOHF (Indofine Chemicals, Hillsborough, NJ, USA)
and ODQ (Cayman Chemical, Ann Arbor, MI, USA). All drugs
were all dissolved in distilled water, with the exception of
indomethacin, which was dissolved in 0.1 mol/l sodium carbonate,
L-NNA, which was dissolved in 0.1 mol/l sodium bicarbonate, ODQ
and TRAM-34, which were dissolved in dimethyl sulfoxide (DMSO).
Statistical analyses
All results are expressed as the mean6s.e.m., n represents the
number of animals per group or the number of assays when tissue
from animals was pooled. Concentration-response curves from rat
isolated mesenteric arteries were computer fitted to a sigmoidal curve
using nonlinear regression (Prism version 5.0, GraphPad Software,
San Diego, CA, USA) to calculate the sensitivity of each agonist
Figure 5. Western blot analysis of protein expression. Western blot of A, eNOS (130 kDa), B, eNOS dimers and monomers (260 kDa) and C,
Nox2 (58 kDa) in the normal and diabetic mesenteric arteries with or without DiOHF treatment. Diabetes significantly reduced the expression of
eNOS and decreased the proportion of eNOS expressed as the dimer, and increased the expression of Nox2. Treatment with DiOHF significant
increased the expression of eNOS, decreased the expression of Nox2 and increased the proportion of eNOS expressed as the dimer. Representative
blots were shown on each corresponding graphs. n = 5–6 experiments. Results are shown as mean6SEM. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0020813.g005
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(pEC50). Maximum relaxation (Rmax) to ACh or SNP was measured
as a percentage of precontraction to phenylephrine. Group pEC50
and Rmax values were compared by one-way ANOVA with post-hoc
analysis using Dunnett’s test or Bonferroni’s selected comparison test
(normal vs. normal+DiOHF, normal vs. diabetic, normal+DiOHF
vs. diabetic+DiOHF and diabetic vs. diabetic+DiOHF) as appropri-
ate. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 KPSS induced maximum contraction in
mesenteric arteries. Exposure of mesenteric arteries from
normal and diabetic rats with or without 39, 49-dihydroxyflavonol
(DiOHF, 1 mg/kg s.c. daily for 7 days) treatment to high K+
physiological saline solution (KPSS, 123 mmol/l). The contraction
to KPSS was not affected by diabetes or DiOHF treatment.
Results are shown as mean6SEM. NS= not significant.
(TIF)
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